Skip to main content
Premium Trial:

Request an Annual Quote

Standigm, Nashville Biosciences Collaborate on AI-Driven Drug Discovery

NEW YORK – Standigm, a Korean company that supports drug discovery with artificial intelligence, said Thursday that it has entered into a collaboration with Nashville Biosciences to accelerate early-stage drug discovery.

Seoul-based Standigm will build customized AI models for drug discovery using de-identified clinical and genomic datasets from Nashville Biosciences. As a wholly owned spinout of Vanderbilt University Medical Center, the latter firm has access to Vanderbilt's BioVU bank of longitudinal medical records and DNA samples.

"Leveraging Nashville Biosciences' data will add great value to our platforms, enabling us to make the most of customizable and explainable features," Standigm Chief Business Officer Carl Foster said in a statement. "We will also be able to better understand the relationship between genetic variants and corresponding phenotypes."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.